Spanish private university contributing to paediatric exercise oncology trials and research ethics governance across European consortia.
Universidad Europea de Madrid is a private Spanish university that has contributed to EU research in two distinct areas: research ethics governance and clinical health intervention science. In the ethics domain, they supported the development of normative frameworks and interactive platforms for research integrity. More recently, their health sciences faculty has engaged in a randomized clinical trial testing precision exercise interventions for children undergoing cancer treatment, combining exercise technology with augmented reality tools to improve quality of life and social participation. The breadth between these two projects suggests involvement from different academic departments rather than a single focused research group.
FORTEe (2021–2026) is a RIA-funded randomized controlled trial testing precision exercise training for children and adolescents undergoing cancer treatment, with augmented reality and quality-of-life outcomes.
EnTIRE (2017–2021) mapped normative frameworks for ethics and research integrity, contributing to an interactive wiki-platform and open-access training resources across multiple policy contexts.
FORTEe integrates augmented reality and exercise technology platforms as delivery mechanisms for clinical interventions in a pediatric oncology population.
EnTIRE involved community engagement, policy diversity analysis, and wiki-based collaborative knowledge sharing for the European research ethics community.
In the first half of their H2020 engagement (EnTIRE, 2017–2021), the university's contribution was firmly in the governance and policy space — normative analysis of research ethics, stakeholder participation design, and open-access training tools. By 2021, their focus shifted entirely to clinical health research, specifically paediatric exercise oncology with a randomized controlled trial, augmented reality tools, and measurable quality-of-life outcomes. This is a significant pivot: from research-about-research (meta-level) to hands-on clinical intervention research, suggesting different faculties are driving EU engagement at different moments.
The university appears to be moving toward applied clinical health research — particularly where digital tools (augmented reality, exercise technology) intersect with oncology and pediatric populations — making them a viable partner for future health technology or digital therapeutics projects.
Universidad Europea de Madrid has participated exclusively as a consortium partner, never as coordinator, across both projects. Their relatively small funding share in EnTIRE (€46,578) suggests a supporting or task-specific role, while the larger FORTEe allocation (€296,764) indicates a more substantive contributor role in clinical execution. With 26 unique partners across 13 countries in just two projects, they appear to integrate well into large, multi-national consortia rather than building repeated bilateral partnerships.
Despite only two projects, the university has connected with 26 distinct consortium partners across 13 countries, reflecting the large consortium structures typical of RIA and CSA projects in health and society pillars. No recurring partner pattern is visible from this limited dataset.
Universidad Europea de Madrid brings a private university's flexibility — faster administrative processes and stronger industry orientation than many public universities — to clinical and policy research consortia. Their FORTEe involvement demonstrates capacity to run randomized controlled trials in a pediatric clinical setting, which is a specific and uncommon contribution for a teaching-focused institution. For consortium builders, they offer a Spanish HES partner with both health sciences clinical capacity and prior experience in research governance and open science frameworks.
